patient | Page 51 | Aplastic Anemia and MDS International Foundation (AAMDSIF) Return to top.

patient

Press Release Gamida Cell Announces FDA Acceptance of Biologics License Application for Omidubicel with Priority Review

BOSTON--(BUSINESS WIRE)--Aug. 1, 2022-- Gamida Cell Ltd. (Nasdaq: GMDA), the leader in the development of NAM-enabled cell therapy candidates for patients with hematologic and solid cancers and other serious diseases, announced today that the U.S. Food and Drug Administration (FDA) has accepted for filing the Company’s Biologics License Application (BLA) for omidubicel for the treatment of patients with blood cancers in need of an allogenic hematopoietic stem cell transplant.

Kendall Downer, MD.

Downer, Kendall
Clinical Assistant Professor of Medicine in the Department of Medicine
UPMC Presbyterian Shadyside Hospital

Kendall Downer, MD is a Clinical Assistant Professor of Medicine in the Department of Medicine, Division of General Internal Medicine, Section of Palliative Care and Medical Ethics at the University of Pittsburgh.  She completed medical school training at the Icahn School of Medicine at Mount Sinai, internal medicine residency at the University of Pittsburgh Medical Center and hospice and palliative medicine fellowship at the University of Alabama at Birmingham.